Open Access

miR‑27b attenuates dexamethasone‑inhibited proliferation and osteoblastic differentiation in MC3T3‑E1 cells by targeting PPARγ2

  • Authors:
    • Huicheng Lv
    • Tieyi Yang
    • Aimin He
    • Mingbo Wang
    • Haisheng Jia
    • Min Ma
    • Siqin Li
  • View Affiliations

  • Published online on: December 10, 2021     https://doi.org/10.3892/etm.2021.11050
  • Article Number: 127
  • Copyright: © Lv et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteoporosis is a metabolic bone illness characterized by low bone density and a high risk of fracture. It is estimated that there are >60 million individuals in China suffering from this disease, which highlights an urgent requirement for the development of novel and safe drugs for the long‑term treatment of osteoporosis. MicroRNAs (miRNAs/miRs) have previously been identified as critical regulators in the progression of osteoporosis. As an intronic miRNA, miR‑27b enhances the osteoblastic differentiation of stem cells from the bone marrow and the maxillary sinus membrane. However, the mechanism underlying miR‑27b in osteoporosis remains to be elucidated. In the present study, MC3T3‑E1 pre‑osteoblasts were treated with dexamethasone (DEX) to establish an in vitro model of osteoporosis. The results of the present study demonstrated that DEX treatment markedly inhibited the viability of MC3T3‑E1 cells, and downregulated the expression level of miR‑27b. The results of reverse transcription‑quantitative PCR, western blotting and dual‑luciferase assays revealed that miR‑27b directly regulated and suppressed the expression of peroxisome proliferator‑activated receptor γ2 (PPARγ2) in MC3T3‑E1 cells. Furthermore, overexpression of miR‑27b by transfection of cells with miR‑27b mimic attenuated DEX‑mediated inhibition of cell viability, alkaline phosphatase (ALP) activity and the expression levels of bone morphogenetic protein‑2 (BMP2), runt‑related protein 2 (Runx2) and osteocalcin (OCN). The results of the present study indicated that miR‑27b alleviated DEX‑inhibited proliferation and osteoblastic differentiation. Moreover, miR‑27b knockdown repressed MC3T3‑E1 cell viability, ALP activity and protein levels of BMP2, Runx2 and OCN. However, these effects were abrogated by small interfering RNA‑mediated PPARγ2 silencing. In conclusion, the results of the present study demonstrated that miR‑27b attenuated DEX‑inhibited proliferation and osteoblastic differentiation in MC3T3‑E1 pre‑osteoblasts by targeting PPARγ2.
View Figures
View References

Related Articles

Journal Cover

February-2022
Volume 23 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lv H, Yang T, He A, Wang M, Jia H, Ma M and Li S: miR‑27b attenuates dexamethasone‑inhibited proliferation and osteoblastic differentiation in MC3T3‑E1 cells by targeting PPARγ2. Exp Ther Med 23: 127, 2022
APA
Lv, H., Yang, T., He, A., Wang, M., Jia, H., Ma, M., & Li, S. (2022). miR‑27b attenuates dexamethasone‑inhibited proliferation and osteoblastic differentiation in MC3T3‑E1 cells by targeting PPARγ2. Experimental and Therapeutic Medicine, 23, 127. https://doi.org/10.3892/etm.2021.11050
MLA
Lv, H., Yang, T., He, A., Wang, M., Jia, H., Ma, M., Li, S."miR‑27b attenuates dexamethasone‑inhibited proliferation and osteoblastic differentiation in MC3T3‑E1 cells by targeting PPARγ2". Experimental and Therapeutic Medicine 23.2 (2022): 127.
Chicago
Lv, H., Yang, T., He, A., Wang, M., Jia, H., Ma, M., Li, S."miR‑27b attenuates dexamethasone‑inhibited proliferation and osteoblastic differentiation in MC3T3‑E1 cells by targeting PPARγ2". Experimental and Therapeutic Medicine 23, no. 2 (2022): 127. https://doi.org/10.3892/etm.2021.11050